NCT03539172

Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study

A Phase II Trial of Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck: the RASS Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 61 (estimated)
• Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
• Sex: Male
• Age: 10 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a non-randomized, phase II, open label study of radiotherapy concurrent with Apatinib Mesylate after surgery in patients with advanced head and neck soft tissue and bone sarcomas. The primary purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate in patients with head and neck soft tissue and bone sarcomas.

Conditions

• Soft Tissue and Bone Tumor
• Head and Neck Cancer
• Sarcoma

Interventions

Type	Name	Description
DRUG	Apatinib Mesylate	Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course

Timeline

• Start date: 2018-06-01
• Primary completion: 2019-12-01
• Completion: 2020-03-01
• First posted: 2018-05-29
• Last updated: 2018-05-30

Locations

1 site across 1 country: China